Inotek Pharmaceuticals (Lexington, MA) a clinical-stage small molecule company focused on age-related macular degeneration, glaucoma, cataract and diabetic retinopathy, closed a $18M Series D financing. Participants include Devon Park Bioventures, Rho Ventures, Care Capital, Pitango Venture Capital, MedImmune Ventures and Bio One Capital.

EyeGate Pharma (Wlatham, MA) a clinical-stage company focused on a non-invasive iontophoresis drug delivery system for ocular therapeutics, closed a $22.6M Series D financing. Participants include Natixis Private Equity, Emerging Capital, Ventech, Innoven Partners and Medicis Capital.

Molecular Partners (Switzerland) a preclinical-stage developing DARPins, a potential new class of protein therapeutics focused on ophthalmology indications, closed a $45M Series B financing. Participants include Essex Woodlands Health Ventures, Index Ventures, Johnson & Johnson Development Corp., BB Biotech Ventures and EndeavourVision.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Ophthotech (Princeton, NJ) a clinical-stage biopharmaceutical company focused on ophthalmic therapies for wet and dry age-related macular degeneration, closed a $30M Series B financing. Participants include Clarus Ventures, SV Life Sciences, Novo Ventures and HBM BioVentures.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Lux Biosciences (Jersey City, NJ) a clinical-stage biotechnology company focused on ophthalmic diseases, closed a $50M Series B financing. Participants include HBM Bioventures, De Novo Ventures, Prospect Venture Partners, SV Life Sciences and International Biotechnology Trust.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Almeria Sciences (Atlanta, GA) a clinical-stage biopharma company focused on ophthalmic disease and treatment of diabetic macular edema, closed a $5M Series C, bringing the total round to $35. Participants have included Polaris Venture Partners, Intersouth Partners, Venrock Associates, Domain Associates and Scale Venture Partners.

Oraya Therapeutics (Newark, CA) an early-stage medical device company focused on radiation treatment of age related macular degeneration, closed a $42M Series C financing. Participants include Domain Associates, Scale Venture Partners, Essex Woodlands Health Ventures and Synergy Life Partners.

Applied Genetic Technlogies (Alachua, Fl) a clinical-stage biopharmaceutical company developing gene therapy treatments for Alpha-1 Antitrypsin Deficiency and Leber’s Congenital Amaurosis, closed a $11.8M Series C financing. Participants include InterWest, Intersouth Partners and MedImmune Ventures.

Visiogen (Irvine, CA) a commercial-stage medical device company focused on products for cataract and refractive patients, closed a $40M Series D financing. Participants include Novartis Venture Fund, Technology Partners, Three Arch Partners, New Leaf Venture Partners, Prospect Venture Partners, CMEA Ventures and Foundation Medical Partners.

iScience Interventional (Menlo Park, CA) a commercial-stage microcatheter device for the treatment of ocular diseases open-angle glaucoma and clinical-stage development focused on wet-AMD, closed a $20.5M Series F financing. Participants include Affinity Capital Management, Johnson & Johnson Development Corp., L Capital Partners, Clarian Health Ventures, Prism VentureWorks, Three Arch Ventures, DeNovo Ventures and Asset Management [...]